maradonna 8888 / Shutterstock.com
The English Court of Appeal has issued the latest ruling in the patent dispute between Warner-Lambert and Actavis concerning Lyrica (pregabalin), says Arty Rajendra of Rouse Legal.
At 10:30am on June 29, a London court room packed full of patent lawyers will fall silent as the trial in Warner-Lambert v Actavis commences.
This case has already attracted significant media attention because it will determine how generic manufacturers market drugs for which the primary patent protection has expired but a second medical use patent for the drug remains valid.
Warner-Lambert, owned by pharmaceutical company Pfizer, markets the drug pregabalin under the brand name Lyrica.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at firstname.lastname@example.org.
If you have any technical issues please email tech support.
Warner-Lambert, Actavis, patent, patent infringement, medical use, pregabalin,